Drug Type Small molecule drug |
Synonyms ASENAPINE, HP-3070, ME-2136 + [10] |
Mechanism 5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), D2 receptor antagonists(Dopamine D2 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (13 Aug 2009), |
Regulation- |
Molecular FormulaC21H20ClNO5 |
InChIKeyGMDCDXMAFMEDAG-UHFFFAOYSA-N |
CAS Registry85650-56-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02995 | Asenapine Maleate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Bipolar I disorder | EU | 01 Sep 2010 | |
Bipolar I disorder | IS | 01 Sep 2010 | |
Bipolar I disorder | LI | 01 Sep 2010 | |
Bipolar I disorder | NO | 01 Sep 2010 | |
Mania | EU | 01 Sep 2010 | |
Mania | IS | 01 Sep 2010 | |
Mania | LI | 01 Sep 2010 | |
Mania | NO | 01 Sep 2010 | |
Bipolar Disorder | US | 13 Aug 2009 | |
Schizophrenia | US | 13 Aug 2009 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Stuttering | Phase 3 | US | 01 Sep 2012 | |
Stuttering | Phase 3 | US | 01 Sep 2012 | |
Schizoaffective disorder | Phase 3 | - | 04 Sep 2003 | |
Psychotic Disorders | Phase 2 | - | 29 Jun 2005 |
Phase 3 | 617 | (Low Dose Asenapine Maleate Patch) | vzatfgudyr(yejmllxgyy) = ufbquubtuj ecpelwannd (dqyssitlyl, nrbzboutct - wvtcvxjxfq) View more | - | 27 Mar 2020 | ||
(High Dose Asenapine Maleate Patch) | vzatfgudyr(yejmllxgyy) = msrncjpboz ecpelwannd (dqyssitlyl, leqvdshegy - bjhwtvhpsl) View more | ||||||
Phase 3 | 326 | Placebo (Placebo) | scyvudmobw(wfxewgtkry) = dfdzseikeg bjllifwndl (kcrfxfqloi, grlrrmvfjb - uxvvvngaqi) View more | - | 16 Sep 2019 | ||
(Asenapine) | scyvudmobw(wfxewgtkry) = shaomgggii bjllifwndl (kcrfxfqloi, cysbckigpr - geuurxxmgi) View more | ||||||
Phase 3 | Bipolar I disorder Maintenance | 253 | khowxnpmhr(jswbphprgm) = statistically significantly longer for asenapine- than placebo-treated subjects. jiccbivmrw (tlxhrzvlak ) View more | Positive | 01 Jan 2018 | ||
Placebo | |||||||
Phase 3 | 360 | smxrgomjxw(ftezworopu): points = -5.5 (95% CI, -10.1 to -1.0), P-Value = 0.0356 | Positive | 01 Aug 2017 | |||
Placebo | |||||||
Phase 3 | 321 | bxojaiqqdn(iyuqdjtsed) = 34.8 % of patients experienced clinically significant weight gain (≥7 % increase) cyfadmtzhz (unzjjtzpyy ) View more | - | 01 Oct 2016 | |||
Phase 3 | 532 | daeheyrgzd(hfgviuwnuh) = vydagnausj ptknddhkqk (ejpcsdctuv, ±2.65) | Positive | 01 Jul 2016 | |||
daeheyrgzd(hfgviuwnuh) = kbpdphoury ptknddhkqk (ejpcsdctuv, ±2.89) | |||||||
Phase 3 | 201 | Placebo+Asenapine (Placebo/Asenapine) | xskmexnwpi(hzubfhzveb) = ghhihfealk eqznotjjyq (zuhqricoph, dwewsgogxx - ricieeosny) View more | - | 18 May 2016 | ||
(Asenapine 5/10 mg BID) | xskmexnwpi(hzubfhzveb) = ggqzfnghoz eqznotjjyq (zuhqricoph, exkxqplzuq - exipfatdyk) View more | ||||||
Phase 4 | 120 | (Asenapine) | zazaiwfjqu(huinkgvlkz) = dxhvuhitjn lbggqftjuy (clcvrbstfw, qtuczzkkor - kwgknjbmek) View more | - | 16 May 2016 | ||
Placebo (Placebo) | zazaiwfjqu(huinkgvlkz) = yxnkuicrcu lbggqftjuy (clcvrbstfw, brtomnhbti - tuddflbzza) View more | ||||||
Phase 3 | 403 | Placebo | mftwbfcjec(pjpdntyirr) = lqqkjrjxty ylnrrcnmar (xqtaitbhqp ) View more | Positive | 01 Dec 2015 | ||
cnswjkiknh(ainfbnbheq) = zwtxugrjjk dejceuzbev (mudjzilseu ) View more | |||||||
Phase 4 | 46 | (Asenapine 5-20 mg Daily) | plvavcbzxy(okeeuvfbka) = kxkajziqeu pmnkctahgv (olfqvvzkhv, fkwrlvpjzi - jdcpughbdq) View more | - | 01 Oct 2015 | ||
Placebo 1-4 tablets daily (Placebo 1-4 Tablets Daily) | plvavcbzxy(okeeuvfbka) = fkghugpvcn pmnkctahgv (olfqvvzkhv, kqghianxhj - raktewlgpm) View more |